Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.
Looking for a particular Context Therapeutics employee's phone or email?
The Context Therapeutics annual revenue was $4 million in 2026.
Martin Lehr is the CEO and Director of Context Therapeutics.
17 people are employed at Context Therapeutics.
Context Therapeutics is based in Philadelphia, Pennsylvania.
The NAICS codes for Context Therapeutics are [54, 541714, 5417, 54171, 541].
The SIC codes for Context Therapeutics are [28, 87, 283, 873].